These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39110200)

  • 1. Myeloproliferative neoplasms: young patients, current data and future considerations.
    Sobas M; Ianotto JC; Kiladjian JJ; Harrison C
    Ann Hematol; 2024 Sep; 103(9):3287-3291. PubMed ID: 39110200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 3. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2V617F mutations in myeloid malignancies: single center experience.
    Panovska-Stavridis I; Cevreska L; Ivanovski M; Stojanovik A; Lozance M; Matevska N; Dimovski A; Serafimoski V
    Prilozi; 2008 Dec; 29(2):257-67. PubMed ID: 19259051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
    Li Y; Zhang XY; Han J; Wang L
    Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
    Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
    Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic-pathologic characterization of myeloproliferative neoplasms.
    Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
    Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.
    Pemmaraju N; Moliterno AR
    Am Soc Clin Oncol Educ Book; 2015; ():139-45. PubMed ID: 25993152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
    Bao M; Zhang M; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
    Acta Haematol; 2023; 146(4):293-306. PubMed ID: 36812897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
    Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
    Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
    Wang J; Hao J; He N; Ji C; Ma D
    Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
    Takenaka K
    Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
    Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
    Int J Lab Hematol; 2024 Aug; 46(4):687-694. PubMed ID: 38665121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current approaches to challenging scenarios in myeloproliferative neoplasms.
    Zimran E; Hoffman R; Kremyanskaya M
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):567-578. PubMed ID: 29575945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.